-
Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
Tuesday, April 17, 2018 - 11:21am | 1124Read More...Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is taking on a broad list of indications with RNAi therapeutics, from bleeding disorders to hypercholesterolemia to amyloidosis. “We’re really building a company that can emerge as a top five biotech company over the next five or so years,...
-
Alnylam Pharmaceutical Surges After Rare Disease Drug Met Key Endpoints
Wednesday, September 20, 2017 - 8:25am | 415Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) surged higher by more than 20 percent early Wednesday morning after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 9:58am | 290Read More...In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...
-
Shares Of Alnylam Pharmaceuticals Lower Following Equity Offering
Wednesday, January 21, 2015 - 11:03am | 109Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) tumbled 4 percent Wednesday morning as the company priced 4.73 million shares of common stock at $95 per share after announcing on Tuesday it plans to initiate a public offering of common stock. All of the shares being offering will be sold by...
-
Glaucus Research Profiles Tekmira Pharmaceuticals; Shares Down 2%
Monday, November 10, 2014 - 2:22pm | 227Read More...Shares of Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) were trading lower on Monday after Glaucus Research highlighted a “Strong Sell” recommendation with a $7 to $10 price target. “Tekmira is hugely overvalued and its share price is poised to collapse,” Glaucus...
